bpi-9016
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT02478866)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545236 ↗
Also known as
- bpi-9016
- bpi-9016m
- bpi-9016m
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02929290 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Betta Pharmaceuticals Co.,Ltd. |
| NCT02478866 | Phase 1 | Aug 1, 2015 | Betta Pharmaceuticals Co.,Ltd., Chinese Academy of Medical Sciences, Tsinghua University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Betta Pharmaceuticals Co.,Ltd. | For profit | 2 | 2 | 2 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Tsinghua University | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1